echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal stromal tumors soon

    Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal stromal tumors soon

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Zai Lab/Deciphera Pharmaceuticals' application for the import of category 5.


    Gastrointestinal stromal tumor (GIST) is a rare gastrointestinal tumor that originates from interstitial cells of Cajal, but it ranks first in soft tissue sarcoma of the gastrointestinal tract and can occur in any gastrointestinal tract.


    Currently, surgery is the only cure for limited or potentially resectable GIST.


    Ripretinib is a drug introduced by Zai Lab from Deciphera in 2019.


    Qinlock's approval is based on the positive results of the Phase III study INVICTUS.


    The results showed that compared with placebo, the progression-free survival of patients in the repetinib treatment group was significantly prolonged (mPFS was 6.


    In addition to the fourth-line treatment of GIST, Peritinib is currently undergoing a Phase III study of the second-line treatment of GIST.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.